(Q35147050)

6 August 2017

title

Hepatitis C virus therapies: current treatments, targets and future perspectives (English)

1 reference

6 August 2017

1 reference

1 reference

Michelle P Walker

1

1 reference

6 August 2017

Todd C Appleby

2

1 reference

6 August 2017

Weidong Zhong

3

1 reference

6 August 2017

Johnson Y N Lau

4

1 reference

6 August 2017

Zhi Hong

5

1 reference

6 August 2017

publication date

1 January 2003

1 reference

Antiviral Chemistry & Chemotherapy

6 August 2017

published in

1 reference

6 August 2017

volume

14

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

1-21

1 reference

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

A novel high throughput screening assay for HCV NS3 helicase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Hepatitis C virus NS3 protease requires its NS4A cofactor peptide for optimal binding of a boronic acid inhibitor as shown by NMR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Complex formation between the hepatitis C virus serine protease and a synthetic NS4A cofactor peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Hepatitis C virus-like particle morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Efficient initiation of HCV RNA replication in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

A mechanism for initiating RNA-dependent RNA polymerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Subcellular Localization and Topology of the p7 Polypeptide of Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Mechanism of La Crosse virus inhibition by ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Amantadine's viral kinetics in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Comparative Analysis of Anti-Hepatitis C Virus Activity and Gene Expression Mediated by Alpha, Beta, and Gamma Interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Isolation and structure of SCH 351633: a novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Molecular cloning and nucleotide sequence of the pestivirus bovine viral diarrhea virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

RNA virus error catastrophe: direct molecular test by using ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Highlights in the development of new antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Comparative characterization of two DEAD-box RNA helicases in superfamily II: human translation-initiation factor 4A and hepatitis C virus non-structural protein 3 (NS3) helicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

A mouse model for hepatitis C virus infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

In search of hepatitis C virus receptor(s).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-alpha2B for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

The RNA helicase and nucleotide triphosphatase activities of the bovine viral diarrhea virus NS3 protein are essential for viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Course and outcome of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

An ELISA for RNA helicase activity: application as an assay of the NS3 helicase of hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Non-peptide inhibitors of HCV serine proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Efficacy of consensus interferon in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Mechanism of ribosome recruitment by hepatitis C IRES RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Towards defining a minimal functional domain for NTPase and RNA helicase activities of the hepatitis C virus NS3 protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Determination of interferon-alpha2 allele composition in the genomic DNA from healthy volunteers and leukemic patients in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Mutations in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Pegylated interferons for the treatment of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

RNA interference in adult mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Hepatitis C advances in antiviral therapy: what is accepted treatment now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

α-Glucosidase inhibitors as potential broad based anti-viral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Protection against persistence of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Hepatitis C virus replication in mice with chimeric human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Hepatitis C virus NS3 and simian virus 40 T antigen helicases displace streptavidin from 5'-biotinylated oligonucleotides but not from 3'-biotinylated oligonucleotides: evidence for directional bias in translocation on single-stranded DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

The combination of interferon alpha-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

The non-structural 5A protein of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Biological evaluation of hepatitis C virus helicase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Characterization of cell lines carrying self-replicating hepatitis C virus RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Binding of hepatitis C virus to CD81

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Hepatitis C virus infection is associated with the development of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Generation of infectious and transmissible virions from a GB virus B full-length consensus clone in tamarins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Ribavirin causes error catastrophe during Hantaan virus replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Identification of two flavivirus-like genomes in the GB hepatitis agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Secondary structure and hybridization accessibility of hepatitis C virus 3'-terminal sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Product inhibition of the hepatitis C virus NS3 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Novel hepatitis C virus protease inhibitors: thiazolidine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

HCV RNA-dependent RNA polymerase as a target for antiviral development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Treatment of chronic hepatitis C patients with amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Å resolution structure in a hexagonal crystal form

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Structure of the hepatitis C virus RNA helicase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Application of structural biology tools in the study of viral hepatitis and the design of antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Expression, purification, and partial characterization of HCV RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Interleukin-12 in the treatment of chronic hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Template/primer requirements and single nucleotide incorporation by hepatitis C virus nonstructural protein 5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

Silencing viruses with RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400101

10.1177/095632020301400101

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference